to infant has been suspected as occumng, particularly in the presence of intact membranes (8). The importance of this mode of transmission of infection, however, is not well understood. It may be that antepartum maternal bacteremia increases the risk to the newborn for acquiring early-onset disease and that preventing newborn early-onset sepsis is dependent on effectively treating or preventing antepartum GBS maternal bacteremia.
Previously described animal models for GBS sepsis have included inoculation of bacteria into amniotic fluid (9) and directly into newborns (5, 10, 11) and have not included maternal infection. This animal model of vertical transmission can be used to study the mechanisms of transmission of GBS from mother to infant and to investigate regimens aimed at preventing earlyonset group B streptococcal infection. 4 . Yow MD, Mason EO, Leeds U, Thompson PK, Clark DJ, Gardner SE 1979 Ampicillin prevents intrapartum transmission of group B streptococcus. GH plays a significant role in the normal development of thymic-dependent immune function in lower mammals (3, 4, 11, 14) . Although immune deficiency states in man are frequently associated with impaired growth, abnormalities of GH secretion has not been implicated in such conditions. Moreover, the precise role of GH in the development and maturation of the thymic-dependent and thymic-independent immune functions in humans is as yet unknown. The purpose of the study was to investigate the immunological responses of children with GH deficiency, before and after GH therapy.
SUBJECTS
Nine children 3-15 yr of age with GH deficiency were investigated. The diagnosis of GH deficiency was based on clinical and biochemical findings. All children were more than 3 SD below the mean height for age, and their growth velocities were 4 cm/yr or less. Skeletal maturation was delayed by more than 2 yr in all cases. At least two stimuli of GH secretion (L-dopa, arginine, insulin-induced hypoglycemia, glucagon) were used to assess pituitary growth hormone responsiveness. In all children, the maximum GH response was less than 5 ng/ml following provocation. In addition to GH concentrations, serum T4, thyroid-stimulating hormone, cortisol, Ca, P, alkaline phosphatase, blood urea nitrogen, creatinine, liver enzymes, bilirubin, total protein, A/G ratio, triglycerides, and cholesterol were determined in all children. These studies all were found to be within normal limits except for the T4 and cortisol levels in one patient who suffered from congenital panhypopituitarism. He was given T4 replacement therapy, but cortisol replacement was withheld because ACTH deficiency was incomplete. The onset of growth deceleration occurred in the first 2 yr of life in five children and beyond age 5 in four children. The interval between presumed onset of GH deficiency and the time of study ranged from 3 to 10 yr.
METHODS
Prior to initiation of GH therapy the following baseline studies were conducted. Humoral immunity was evaluated by quantitation of B lymphocytes by the EAC method (9); immunoglobulins were quantified by radioimmunodiffusion (7). Cell-mediated immunity was assessed by quantitation of T lymphocytes by the E rosette technique (16), by assessing the PHA lymphoproliferative response (lo), and by delayed hypersensitivity skin tests (mumps, SK-SD, PPD, and candida). The studies were repeated at 3 months and at 9-1 2 months following GH therapy. GH was measured by radioimmunoassay by methods previously described (12). GH for treatment of the children was provided by the National Hormone and Pituitary Program. A dose of 0.1 U/kg body weight was injected three times weekly on an alternate day basis. The effectiveness of GH therapy was demonstrated by a significant increase in linear growth ranging from 6-10 cm/yr in each child. One child developed GH antibodies after 12 months of therapy with subsequent diminution of her growth response. Informed and written consent was obtained from parents and children when applicable.
RESULTS
Baseline immunological studies and results following GH therapy are shown in Table 1 . The PHA response 74.1 + 37.6 (mean + SD), and the T rosette 58.3% f 9.4, E rosette 2 1.1 % + 6.1, IgG 810 + 241, IgA 140.5 + 85, and IgM 176.2 f 70 mg/dl concentrations in GH-deficient children were comparable to age adjusted values in normal children (15). There was a gradual increase in the PHA-stimulated lymphoproliferative response which reached a significant level 9-12 months posttherapy, 123.2 + 5 1.9 versus 74.1 +: 37.6, p < 0.05. T and B rosettes and immunoglobulin concentrations were not affected by GH therapy (Table I) . Delayed hypersensitivity skin tests to PPD, dermatophyton, and mumps remained unchanged. SK-SD responses converted from negative to positive in two children, and the magnitude of response changed in two others; results remained unchanged in the rest.
DISCUSSION
In vivo and in vitro studies in the pituitary dwarf mouse and the neonatally thymectomized mouse have demonstrated a direct and specific pituitary-thymic relationship (3, 1 1) . In the pituitary dwarf mouse after weaning, lymphopenia develops and the thymus and peripheral lymphoid tissue progressively involute. Administration of GH increases the weight of lymphoid tissue, restores antibody responsiveness, and enables the dwarf mouse to reject allografts (6). The anterior pituitary of the neonatally thymectomized mouse on the other hand, contains enlarged degranulated acidophilic cells suggesting a feedback control of thymus on the pituitary (4). In vitro, the presence of GH is necessary for the generation of cytotoxic lymphocytes (1 3), and specific saturable GH receptors have been identified on the surface of thymocytes (2) .
Although an association of immunodeficiency and shortlimbed dwarfism, without GH deficiency, has been described (I), an unusual susceptibility to or increased incidence of infections has not been observed in GH-deficient children.
In ataxia teleangiectasia certain endocrine deficiencies may be present. However, GH deficiency has not been implicated. Fleisher et al. (8) described a family with four affected members who presented with isolated GH deficiency and hypogammaglobulinemia. Three of the affected members studied prior to GH therapy had no detectable B lymphocytes in peripheral blood. In the fourth case treated with GH for 2 yr, 1 to 3% of the peripheral lymphocytes were identified as B lymphocytes and the serum IgA and IgM levels were normal. The authors raise the possibility of a GH effect on this patient's immunological system. Follow-up studies are not available on the two cases who were diagnosed at a young age and studied prior to GH therapy.
Children with GH deficiency investigated in this study experienced no unusual susceptibility to bacterial or viral agents and their baseline immunological functions were intact. Following an extended period of GH therapy, no significant changes occurred in the immunological parameters tested. The increase in PHA-stimulated lymphoproliferative response observed following therapy is attributable to a tissue specific nuclear effect of GH on lymphoid cells (5).
We considered the possibility that our inability to demonstrate a pronounced GH effect might be related to the lack of absolute GH deficiency in these children. In addition, in those suffering from acquired GH deficiency, immune competency may not regress, as is the case in neonatally hypophysectomized mouse. Eight of the nine children studied demonstrated some GH response, albeit minimal, to various GH stimuli. Therefore, absolute GH deficiency did not exist. In one child with congenital pituitary hypoplasia and no detectable GH at the time of testing, the PHA stimulation resvonse index was low (28). and markedly increased (to 204), 3 months following GH $erapy. In this particular case, however, T and B lymphocytes, immunoglobulin concentrations and hypersensitivity skin tests all were normal.
The GH treatment regimen employed in this study does not restore serum GH concentrations to physiological levels. The intermittent therapy, however, has been effective in promoting growth and in generation of insulin-like growth factors dependent on the biological action of GH. Our inability to demonstrate a measured response in the several immune parameters studied may be attributable to the normal baseline immunological parameters observed in these children prior to GH therapy.
In summary, immunological function in children with GH deficiency appears intact as evidenced clinically by a lack of undue susceptibility to infectious agents, and immunologically, by normal values of various immune parameters. GH therapy does not lead to any detectable alterations in humoral or cellular immunity. An investigation of the effect of GH on subpopulations of lymphocytes would be of interest. However, at the time our study was conducted these techniques were not available in our laboratory.
